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Abstract
The hepatitis B virus (HBV) has been classified into eight genotypes (A-H) based on intergenotypic divergence of at
least 8% in the complete nucleotide sequence or more than 4% in the S gene. To facilitate the investigation of the
relationship between the efficacy of drug treatment and the mutation with specific genotype of HBV, we have
established a new genotyping strategy based on a fragment of the HBV DNA polymerase gene. Pairwise sequence
and phylogenetic analyses were performed using CLUSTAL V (DNASTAR) on the eight (A-H) standard full-length
nucleotide sequences of HBV DNA from GenBank (NCBI) and the corresponding semi-nested PCR products from
the HBV DNA polymerase gene. The differences in the semi-nested PCR fragments of the polymerase genes
among genotypes A through F were greater than 4%, which is consistent with the intergenotypic divergence of at
least 4% in HBV DNA S gene sequences. Genotyping using the semi-nested PCR products of the DNA polymerase
genes revealed that only genotypes B, C, and D were present in the 50 cases, from Shenyang, China, with a
distribution of 11 cases (22%), 25 cases (50%), and 14 cases (28%) respectively. These results demonstrate that our
new genotyping method utilizing a fragment of the HBV DNA polymerase gene is valid and can be employed as a
general genotyping strategy in areas with prevalent HBV genotypes A through F. In Shenyang, China, genotypes C,
B, and D were identified with this new genotyping method, and genotype C was demonstrated to be the
dominant genotype.
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Background
Hepatitis B virus (HBV) infection is a substantial public
health problem, with approximately 400 million virus
carriers worldwide [1]. The infection can cause acute
and chronic liver diseases, including cirrhosis and hepa-
tocellular carcinoma (HCC) [1]. HBV has been classified
into eight genotyped, designated as A-H, based on inter-
genotypic divergence of at least 8% in the complete
nucleotide sequence or more than 4% in the S gene
[2-8]. HBV genotypes have distinct geographical distri-
butions and correlate with the severity of liver diseases.
HBV genotype C is associated with more severe liver
diseases than genotype B [9-11], and patients infected
with genotype D appear to have a higher incidence of
HCC [12], a higher risk for HBV recurrence, and a
higher mortality rate after liver transplantation [13] than
patients with genotype A. In addition, patients with
HBV genotypes C and D have a lower response rate to
treatment with IFN-a compared to those with genotypes
A and B [9]. Genotype may also influence the emer-
gence of lamivudine resistance mutations, which appear
to be more strongly associated with genotype A than
genotype D [14,15]. Therefore, HBV genotyping is of
great importance in guiding treatment, improving vacci-
nation, and controlling liver diseases.
In the past, genotyping was mostly performed on the
full-length nucleotide sequence or the S gene sequence
[2-8]. In order to facilitate the study of drug treatments,
particularly how lamivudine resistance develops from
polymerase gene mutations [14,15], we established a
new genotyping method using a fragment of the HBV
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the S gene. This genotyping method differs from past
methods and aids in investigating the relationship
between the efficacy of drug treatment and muations in
specific genotypes of HBV.
Methods
Serum sample collection
Serum samples were collected with consent from
patients and in accordance with Chinese State Ethics
Regulation. This study included 33 patients with chronic
hepatitis B with clinical symptoms (22 males, 11
females, mean age 31.79 years) that were to receive anti-
virus treatment of lamivudine and 20 asymptomatic car-
riers (12 males, 8 females, mean age 29.5 years) that
were enrolled as a control group. Chronic infection was
defined as the detection of hepatitis B surface antigen
(HBsAg) for at least 6 months. Among these samples,
we found no co-infections with either human immuno-
deficiency virus or hepatitis C virus. All patients were
born in Shenyang, China. The serum samples were col-
lected and stored at -70°C.
Primer design
The genome of HBV consists of four open reading
frames, including the envelope gene (PreS/S), the core
gene (PreC/C), the polymerase gene, and the gene
encoding the transactivating protein X (X). Because of
the compact organization of the genome, the complete
PreS/S gene, part of the PreC/C gene and the X gene
overlap with the polymerase gene. The S gene (nucleo-
tides 155 to 833) encodes the major envelope proteins
[16,17].
With the aid of DNASTAR software, we designed
three primers to the sequence of the HBV DNA poly-
merase gene (accession number AF100309), named
HBV381 (nt381-402), HBV840 (nt840-861), and
HBV801 (nt801-822). The primers were synthesized
(TaKaRa Biotechnology Co., Ltd., China) with the
sequences of 5"-TGCGGCGTTTTATCATCTTCCT-3”,
5"-GTTTAAATGTATACCCAAAGAC-3”,a n d5 " -
CAGCGGCATAAAGGGACTCAAG-3”, respectively.
Two pairs of semi-nested polymerase chain reaction
(PCR) primers (HBV381/HBV840 and HBV381/
HBV801) were utilized in the amplification reaction
while primer HBV381 was used in the sequencing reac-
tion. The amplified fragment of the polymerase gene
overlaps slightly with the S gene.
Polymerase gene fragment amplification and sequencing
HBV DNA was extracted from 55 serum samples
obtained from infected patients. The fragment of the
polymerase gene was amplified by semi-nested PCR
with two rounds of amplification. The reaction volume
was 50 μl. The first round of amplification was per-
formed with an initial 5 min denaturing step at 94°C,
followed by 30 cycles of denaturing for 45 s at 94°C,
annealing for 30 s at 50°C, and elongation for 90 s at
72°C, with a final extension period of 10 min at 72°C
using primers HBV381 and HBV840. The second round
of amplification was performed with an initial 5 min
denaturing step at 94°C, followed by 30 cycles of dena-
t u r i n gf o r4 5sa t9 4 ° C ,a n n e a l i n gf o r3 0sa t5 5 ° C ,a n d
elongation for 60 s at 72°C, with a final extension period
of 10 min at 72°C using primers HBV381 and HBV801.
The reaction products of the semi-nested PCR were
visualized on a 2% agarose gel stained with ethidium
bromide. The semi-nested PCR reaction products were
subjected to purification and sequencing using the
HBV381 primer through a commercial company
(Shanghai GeneCore Bio Technologies Co., Ltd. Shang-
hai, China) on an ABI sequencing system.
Homology and phylogenetic analyses
The eight standard full-length nucleotide sequences of
H B VD N Aw e r eo b t a i n e df r o mG e n B a n k( N C B I ) ,
including genotypes A (accession number AY128092), B
(AB073858), C (AF461359), D (AY090453), E (X75664),
F (X75663), G (AF405706), and H (AY090460). Nucleo-
tide sequences of approximately 262 base pairs (bp)
from the primer HBV381 were used for homology and
phylogenic analysis. The eight standard nucleotide
sequences of the HBV DNA genotypes, the predicted
sequence of the semi-nested PCR products, and the
actual sequences of the products were analyzed in pairs
using CLUSTAL V (DNASTAR).
Statistical analysis
T h eg e n o t y p i n gd a t aw e r ea n a l y z e du s i n gac
2 test (SAS
software, Cary, NC).
Results
Most HBV patients screen positive for the HBV
polymerase gene by semi-nested PCR
The purpose of the semi-nested PCR was to screen for
polymerase gene-positive patients. The PCR reaction
products were the expected size (415 bp, Figure 1). In
total, 50 samples (91%) were positive for polymerase
gene fragments, 17 (85%) of which were from asympto-
matic carriers and 33 (100%) of which were from
patients with chronic hepatitis B. All the positive semi-
nested PCR reaction products were then sequenced.
Differences between genotypes (A-F) by analyzing the
homology and phylogeny of the fragments intercepted
from eight standard nucleotide sequences
Homology and phylogenetic analysis of the eight stan-
dard genotype full-length nucleotide sequences were
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tide sequence between genotypes D and E was 7.9%,
which was the smallest among all the genotypic differ-
ences. The largest difference in nucleotide sequence was
found between genotypes B and H and between geno-
types G and H, both of which were 15.9% (Figure 2a,
Table 1). The results were consistent with an intergeno-
typic divergence of at least 8% in the complete nucleo-
tide sequence [2-7]. Homology and phylogenetic analysis
of the semi-nested PCR fragments (262 bp) from the
DNA polymerase genes of the standard strains revealed
that the differences between genotypes A and G, B and
G, and F and H were 3.5%, 3.1%, and 3.1%, respectively
(Figure 2b, Table 2). However, all the other differences
between pairs of genotypes (A-F), such as between gen-
otypes A and B, A and C, B and C, etc., were greater
than 4%, consistent with an intergenotypic divergence of
at least 4% in HBV DNA S gene sequences [8].
Genotypes B, C and D by genotyping the sequencing
results of the semi-nested PCR products with the
intercepted fragments of the standard genotypes
polymerase gene
O n l yg e n o t y p e sB ,C ,a n dDw e r ed e t e c t e di nt h e5 0
HBV DNA-positive cases, occurring in 11 (22%), 25
(50%), and 14 cases (28%), respectively (Figure 3, Table
3). The proportions of these genotypes were significantly
different ((p = 0.000) and the proportions of genotypes
C and B and genotypes C and D were significantly dif-
ferent (p < 0.05). Of the 33 patients with chronic hepati-
tis B, genotypes B, C, and D were detected in 7 (21%),
18 (55%), and 8 cases (24%), respectively. The propor-
tions of these genotypes were significantly different (p =
0.001) and the proportions of genotypes C and B and
Figure 1 Polyacrylamide gel electrophoresis of the reaction
products of semi-nested PCR and DNA Markers. The first round
of amplification products (1), the second round of amplification
products (2), and the negative control (NC) are shown.
Figure 2 (a) Phylogenetic tree of the full-length nucleotide
sequences of the eight HBV DNA standard genotypes (HBV
GENOTYPE A-H). (b) Phylogenetic tree of the nucleotide sequences
of the fragments of the eight HBV DNA standard genotype
polymerase genes (hbv A-H).
Table 1 Homology of eight HBV DNA standard genotype
full-length nucleotide sequences (%)
Genotype HBV
A
HBV
B
HBV
C
HBV
E
HBV
F
HBV
G
HBV
H
HBV
D
HBV A *** 90.3 91.2 88.9 85.7 87.4 84.9 89.2
HBV B 9.5 *** 89.3 87.1 84.8 85.5 84.3 87.6
HBV C 8.5 10.3 *** 88.5 85.5 86.2 85.4 88.0
HBV E 10.5 12.3 10.5 *** 85.1 88.5 84.6 91.5
HBV F 14.3 15.5 14.4 14.7 *** 84.3 91.3 85.2
HBV G 11.8 13.9 13.1 11.3 15.5 *** 84.0 87.6
HBV H 15.1 15.9 14.5 15.2 8.6 15.9 *** 84.8
HBV D 10.5 12.1 10.4 7.9 14.8 12.1 15.5 ***
Bold numbers below *** indicate intergenotypic divergence of the two HBV
DNA standard genotypes.
Table 2 Homology of the fragments of the eight HBV
DNA standard genotype polymerase gene nucleotide
sequences (%)
Genotype HBV
A
HBV
B
HBV
C
HBV
D
HBV
E
HBV
F
HBV
G
HBV
H
HBV A *** 95.4 93.5 91.2 92.0 89.3 96.6 91.6
HBV B 4.4 *** 95.8 92.3 94.6 92.3 96.6 93.9
HBV C 6.0 4.0 *** 94.3 94.6 90.8 93.9 92.0
HBV D 8.1 7.2 5.6 *** 92.7 91.6 92.0 92.0
HBV E 8.1 5.6 5.2 6.4 *** 92.7 93.5 92.3
HBV F 10.3 7.2 8.5 8.1 7.2 *** 91.2 96.9
HBV G 3.5 3.1 5.6 7.2 6.4 8.1 *** 93.5
HBV H 8.5 6.4 8.1 7.7 7.2 3.1 6.4 ***
Bold numbers below *** indicate intergenotypic divergence of the two
fragments of the P gene nucleotide sequences.
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0.05). Of the 17 asymptomatic carriers of HBV, geno-
types B, C, and D were detected in 4 (24%), 7 (41%),
and 6 cases (35%), respectively. The proportions of these
genotypes were not significantly different (p = 0.053).
There was no significant different in the proportions of
these genotypes between patients with chronic hepatitis
B and HBV asymptomatic carriers. While the proportion
of genotype D was similar to genotype B and slightly
lower than genotype C in all the groups analyzed, the
proportion of genotype D was 35% in asymptomatic car-
riers of HBV and only 24% in patients with chronic
hepatitis B (p = 0.410). Genotypes A, E, F, G, and H
were not detected in any cases.
Discussion
Simple and effective alternatives to the gold standard
method for genotyping HBV of sequencing the entire
Figure 3 Phylogenetic tree of the nucleotide sequences of the fragments of the semi-nested PCR products and HBV DNA standard
genotype polymerase genes. Patients with chronic hepatitis B (P-), asymptomatic carriers of HBV (C-), and the fragments of the standard
genotype polymerase genes (hbv A-H) are shown. Only genotypes B, C, and D were detected in the 50 HBV DNA-positive cases.
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fragment length polymorphism [18], multiplex PCR with
type-specific primers [19-21], and others. However, most
of these newer methods are based on analyzing the S gene.
Here we have developed a novel genotyping method based
on a segment of the HBV DNA polymerase gene. Using
C L U S T A LV ,w ed e m o n s t r a t e dt h a tt h ee i g h ts t a n d a r d
genotypes selected from the GenBank (NCBI) had interge-
notypic divergence of at least 8% in their complete nucleo-
tide sequences [2-7]. We then confirmed that the semi-
nested PCR products from the DNA polymerase gene had
intergenotypic divergence of at least 4%, which is in accor-
dance with the HBV DNA S gene sequence [8], except
between genotypes A and G, B and G, and F and H. How-
ever, the intergenotypic divergence among genotypes A
through F were higher than 4% in our selected region.
Genotypes F and H have only been detected in Central
and South America, and genotype G has been identified in
France, Germany, Mexico, and the United States. Geno-
type A is more prevalent in northwestern Europe, North
America, India, and sub-Saharan Africa. Only genotypes
B, C, D, and A have been found in China [22-30]. There-
fore, the fragment of HBV DNA polymerase gene can be
used for genotyping hepatitis B in China. This genotyping
method can also be used to predict antiviral therapeutic
response among HBV genotypes and the development of
drug resistant due to mutations. It is a valuable tool for
guiding the treatment of lamivudine-resistant HBV in the
clinical setting [27-30].
We analyzed the nucleotide sequences of the semi-
nested PCR products of the HBV DNA polymerase gene
in the 50 patient samples using CLUSTAL V. Genotypes
C, B and D were detected while genotypes A, E, F, G,
and H were not. Half of the HBV DNA polymerase-
positive samples were genotype C, making it the domi-
nant genotype. It was also the major genotype (55%) in
the 33 patients with chronic hepatitis B. The differences
in the proportions of genotypes B, C, and D were not
significant in the 17 asymptomatic carriers of HBV. The
proportion of genotype D was similar to genotype B,
and its proportion in asymptomatic carriers of HBV was
slightly, but not significantly (p = 0.410), higher than
that in patients with chronic hepatitis B. Our results
suggest that genotype C is the dominant genotype
among asymptomatic carriers and that genotype D may
be more frequent in asymptomatic carriers than in
patients with chronic hepatitis B.
Conclusions
A new method of genotyping HBV via sequencing a frag-
ment of its DNA polymerase gene is a valid strategy for
genotyping hepatitis B in areas with a high prevalence of
genotypes A through F. It provides a novel alternative to
complete sequencing of the HBV genome and allows the
study of the relationship between genotype and muta-
tions of HBV DNA polymerase gene induced by antiviral
therapy. Using this method, genotypes C, B, and D were
identified in patients from Shenyang, China, and geno-
type C was demonstrated to be the dominant genotype.
However, analysis of the difference in the proportions of
the genotypes between asymptomatic carriers of HBV
and patients with chronic hepatitis B, as well as the
impact of genotype on therapeutic response and virus
mutation, require further study.
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